Helsinn Therapeutics

AKYNZEO

Manufacturer:

Helsinn Therapeutics

Akynzeo HCPCS:

J8655

HCPCS Code Descriptor:

Netupitant 300 mg and palonosetron 0.5 mg, oral

Category:

J Code

Akynzeo NDCs:

69639-0101-01

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Route of Administration:

Oral

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Akynzeo:

AKYNZEO is an Oncology-Anti-Emetic drug manufactured by Helsinn Therapeutics and administered via the Oral route of administration. The J Code: J8655 is aligned to the drug AKYNZEO.

AKYNZEO is an oral anti-emetic used to prevent acute and delayed nausea and vomiting associated with chemotherapy. It is commonly used in combination with dexamethasone and is indicated for use in adults. AKYNZEO (J8655) uses a combination of netupitant and palonosetron. Netupitant works by selectively binding neurokinin-1 receptors, whose activation are largely associated with delayed emesis. Palonosetron acts as a 5-HT3 receptor antagonist and prevents activation of 5-HT3 receptors by serotonin, which is largely associated with acute emesis. Patient assistance for this medication is available through the Helsinn Cares program.

ACCESS PRICING AND MORE BY REGISTERING

J8655 Added Date:

January 1, 2016

J8655 Effective Date:

January 1, 2019

J8655 Termination Date:

HCPCS Active

Akynzeo billing and coding information can be found through Helsinn Therapeutics at the link below:
Akynzeo patient assistance information can be found through Helsinn Cares at the URL: https://helsinnreimbursement.com/
AKYNZEO prescribing information can be found at the link below:
Information regarding AKYNZEO’s side effects can be found at MedlinePlus